AI assistant
COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2025
Aug 20, 2025
32163_dirs_2025-08-20_e0c168d2-1a89-4a1a-a6b8-f37dde447253.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2025-08-18
Reporting Person: Dreyer Scott (EVP & Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-08-18 | Common Stock | M | 16389 | $21.34 | Acquired | 120002 | Direct |
| 2025-08-18 | Common Stock | S | 16389 | $38.2068 | Disposed | 103613 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-08-18 | Stock Option (Right to Purchase) | $21.34 | M | 16389 | Disposed | 2030-02-05 | Common Stock (16389) | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.
F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The option is fully vested and exercisable.